StephChene's profile picture. PharmD. Working in pharma Medical. All tweets/likes are my own. Interested in uro-oncology personal account

StephanieChene

@StephChene

PharmD. Working in pharma Medical. All tweets/likes are my own. Interested in uro-oncology personal account

StephanieChene reposted

ATU (de cohorte) du lutécium dans le cancer de la prostate métastatique effective après l'octroi par @ansm. L'accès précoce aux molécules innovantes, un enjeu majeur pour les patients @GustaveRoussy @unicancer @GETUG_Unicancer @AFUrologie @CerhomAsso ansm.sante.fr/tableau-atu-rt…


StephanieChene reposted

All data of RCTs are with conventional imaging, but half of the #APCCC21 panel is already using novel imaging like PSMA PET-CT. Will Rogers anyone?

piet_ost's tweet image. All data of RCTs are with conventional imaging, but half of the #APCCC21 panel is already using novel imaging like PSMA PET-CT. Will Rogers anyone?

StephanieChene reposted

#ESMO21: 🙌👏 Great presentation Dr Fizazi on the VISION trial!! We are proud having you on the @APCCC_Lugano panel for 2021 and 2022. PSMA-based therapies will be discussed in detail and many questions around this topic will be voted on by the expert panel.

APCCC_Lugano's tweet image. #ESMO21: 🙌👏 Great presentation Dr Fizazi on the VISION trial!!

We are proud having you on the @APCCC_Lugano panel for 2021 and 2022. PSMA-based therapies will be discussed in detail and many questions around this topic will be voted on by the expert panel.

StephanieChene reposted

Impressive results of the VISION study of Lu177-PSMA-617 in PSMA-positive mCRPC with significant PFS and OS benefit!! #ASCO21 @ASCO @ASCOPost @ASCO_pubs @OncoAlert @urotoday

DrChoueiri's tweet image. Impressive results of the VISION study of Lu177-PSMA-617 in PSMA-positive mCRPC with significant PFS and OS benefit!! #ASCO21 

@ASCO @ASCOPost @ASCO_pubs 
@OncoAlert @urotoday
DrChoueiri's tweet image. Impressive results of the VISION study of Lu177-PSMA-617 in PSMA-positive mCRPC with significant PFS and OS benefit!! #ASCO21 

@ASCO @ASCOPost @ASCO_pubs 
@OncoAlert @urotoday
DrChoueiri's tweet image. Impressive results of the VISION study of Lu177-PSMA-617 in PSMA-positive mCRPC with significant PFS and OS benefit!! #ASCO21 

@ASCO @ASCOPost @ASCO_pubs 
@OncoAlert @urotoday
DrChoueiri's tweet image. Impressive results of the VISION study of Lu177-PSMA-617 in PSMA-positive mCRPC with significant PFS and OS benefit!! #ASCO21 

@ASCO @ASCOPost @ASCO_pubs 
@OncoAlert @urotoday

StephanieChene reposted

#TheraP @ANZUPtrials #ASCO20 abstract live. More men with mCRPC had PSA reduction >50% with Lu-PSMA vs cabazitaxel (66% vs 37%). Oral presentation 29 May. Congrats to all @DrMHofman @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia @PeterMacCC

ANZUPtrials's tweet image. #TheraP @ANZUPtrials #ASCO20 abstract live. More men with mCRPC had PSA reduction >50% with Lu-PSMA vs cabazitaxel (66% vs 37%). Oral presentation 29 May. Congrats to all @DrMHofman @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia @PeterMacCC
ANZUPtrials's tweet image. #TheraP @ANZUPtrials #ASCO20 abstract live. More men with mCRPC had PSA reduction >50% with Lu-PSMA vs cabazitaxel (66% vs 37%). Oral presentation 29 May. Congrats to all @DrMHofman @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia @PeterMacCC

StephanieChene reposted

Excited to see the 1st randomised study of Lu-177-PSMA-617 @ANZUPtrials #TheraP as an #ASCO20 oral featured presentation. Congratulations @DrMHofman @Prof_IanD & all investigators & participants @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia

ANZUPtrials's tweet image. Excited to see the 1st randomised study of Lu-177-PSMA-617 @ANZUPtrials #TheraP as an #ASCO20 oral featured presentation. Congratulations @DrMHofman @Prof_IanD & all investigators & participants @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia

StephanieChene reposted

Many thanks to @GabrielMalouf and His guest of honour N Tannir @MDAndersonNews for hosting this 2 days outstanding and inspiring meeting on RCC at Strasbourg.

AbRoumani's tweet image. Many thanks to @GabrielMalouf and His guest of honour N Tannir @MDAndersonNews for hosting this 2 days outstanding and inspiring meeting on RCC at Strasbourg.
AbRoumani's tweet image. Many thanks to @GabrielMalouf and His guest of honour N Tannir @MDAndersonNews for hosting this 2 days outstanding and inspiring meeting on RCC at Strasbourg.

Loading...

Something went wrong.


Something went wrong.